Surgery News and Research

RSS

NanoBio presents preclinical data of NB-201 for treating burn wounds at the 2009 ICAAC

NanoBio Corporation today announced compelling preclinical data for NB-201, a nanoemulsion-based topical lotion for the treatment of burn wounds. In preclinical studies, NB-201 dramatically reduced the severity of burn wound infections as well as inflammation following thermal injuries. The research was conducted at the University of Michigan Medical School in Ann Arbor as a collaborative effort between the University and NanoBio.

15 Sep 2009

Oil-and-water-based nanoemulsion could be more effective for treating burns

Treating second-degree burns with a nanoemulsion lotion sharply curbs bacterial growth and reduces inflammation that otherwise can jeopardize recovery, University of Michigan scientists have shown in initial laboratory studies.

15 Sep 2009

Mortality index can be misleading in major specialties

A key statistic that consumer groups and the media often use when compiling hospital report cards and national rankings can be misleading, researchers report in a new study.

15 Sep 2009

Engineering researchers receive funds to design liver mimics

Virginia Tech College of Engineering researchers will use more than $1 million in grant funding to study engineered tissues that mimic the liver, one of the human body's most complex organs.

15 Sep 2009

New critical illness plan from Colonial Life introduced

A new critical illness plan from Colonial Life & Accident Insurance Company can help many working Americans who may be one serious medical issue away from financial problems. Even with good health insurance, a serious illness, such as a heart attack or stroke, could leave employees on the hook for huge expenses.

15 Sep 2009

America’s Affordable Health Choices Act helps breast cancer patients recuperate easily

The Breast Cancer Survivor Coalition for Advancement, Reform and Equity (Because we Care) today praised a House of Representatives committee for adopting an amendment to the “America’s Affordable Health Choices Act” (H.R. 3200) that would remove barriers to care for breast cancer survivors.

15 Sep 2009

Breast Preservation Foundation stresses on the importance public health education programs

Amidst the ongoing health-policy debate, Los Angeles surgeon Joel Aronowitz, M.D., founder of the Breast Preservation Foundation, furthered his organization’s health education and quality of care mission by meeting Washington policymakers to discuss how health care reform can help breast cancer patients be informed of all their treatment choices and have access to more advanced techniques like skin-sparing mastectomy.

15 Sep 2009

Development of noninvasive imaging and treatment of the heart chronicled in a new article

Fifty-one years ago the average American home cost $30,000, Elvis Presley wooed listeners with Hard Headed Woman, and the hula hoop was introduced. That same year, 1958, a team comprised of a groundbreaking engineer -- Dean Franklin -- in concert with two exceptional physicians -- Drs. Robert Rushmer and Robert Van Citters - was laying the foundation for what would eventually become a radical new approach to health care: the noninvasive imaging and treatment of the heart.

15 Sep 2009

Carotid and cardiac procedures result in higher incidence of post-operative strokes

Among patients undergoing cardiac surgery, post-operative stroke occurred in approximately 2 percent, was not correlated with significant carotid artery narrowing, but was more common among patients who had combined cardiac and carotid procedures, according to a report in the September issue of Archives of Neurology, one of the JAMA/Archives journals.

14 Sep 2009

Phase 1 trial results of Achaogen's ACHN-490 announced at ICAAC meeting

Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, today announced the results of a Phase 1 trial and preclinical data on its lead drug candidate ACHN-490 at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting in San Francisco, CA.

14 Sep 2009

Malnutrition, poor sanitary conditions and HIV leads to defective immune system

The most common causes worldwide include malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection. Other causes of temporary or permanent damage to the immune system include old age, medications (e.g. cortisone, cytostatic drugs), radiotherapy, stress after surgery and malignant tumors of the bone marrow and the lymph nodes.

14 Sep 2009

FDA clearance for PRO-STIM bone graft substitute

Wright Medical Group, Inc., a global orthopaedic medical device company, today announced the 510K clearance of PRO-STIM™ Injectable Osteoinductive Bone Graft Substitute. PRO-STIM™ graft is a composite grafting material that is injected through a small needle, hardens, and is replaced by the patient’s new bone over time.

14 Sep 2009

Clinical study paper on TMR therapy with autologous stem cells presented

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that a paper on a clinical study utilizing its Transmyocardial Laser Revascularization (TMR) therapy in conjunction with autologous stem cells was presented at ESC Congress 2009, the annual meeting of the European Society of Cardiology, in Barcelona, Spain.

14 Sep 2009

Tenet announces revisions to its outlook for 2009

Tenet Healthcare Corporation (NYSE: THC) today announced revisions to its outlook for 2009 Adjusted EBITDA to a new range of $900 million to $950 million. The prior outlook range was $810 million to $875 million. This new range corresponds to an outlook for net income attributable to shareholders in a range of $76 million to $141 million. Adjusted EBITDA is a non-GAAP term defined and reconciled to GAAP net income below.

14 Sep 2009

Spinal implants market to grow in the coming years: iData Research

According to a new market research report by iData Research, the leading international authority in medical device, dental and pharmaceutical market research, the U.S. market for spinal motion preservation devices is estimated to reach $2.54 billion by 2015. The global market for minimally invasive surgery (MIS) is also estimated to see double digit growth, with these two segments driving the overall market for spinal implants, MIS and VCF devices.

14 Sep 2009

Sunlight Research's report analyzes Amgen EPO US patent portfolio

Sunlight Research((TM)) - The Source for Patent Analysis today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio.

14 Sep 2009

Multi-topic, hour-long series hosted by a cardiac surgeon premiers today

"The Dr. Oz Show," a high octane, multi-topic hour-long series hosted by trusted health expert, best-selling author, and world-renowned cardiac surgeon Dr. Mehmet Oz, premieres in syndication today (check local listings). Episodes airing during its premiere week feature two of the recently announced "Core Team Oz" guest contributors, fashion and style expert Tim Gunn ("Project Runway") and fitness specialist Bob Harper ("The Biggest Loser"). Also debuting this week as a member of Core Team Oz is "America's vet," Dr. Marty Becker, the popular author and regular veterinary contributor on ABC-TV's "Good Morning America."

14 Sep 2009

Innovative stroke treatment device to minimize brain damage

Driven by the emergency-room maxim, "Time is brain," NeuroInterventions, Inc. is prototyping an innovative stroke treatment device designed to speed up the restoration of blood flow and thus minimize brain damage.

14 Sep 2009

Study reveals feasibility of OrbusNeich's Genous stent in patients needing undeferrable non-cardiac surgery

OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).

14 Sep 2009

Titan Medical entitles shareholders to purchase common share at $0.24

Titan Medical Inc. announces that its board of directors has approved the grants of 653,680 options to directors and senior officers of the company and 50,974 options to consultants of the company. Each option entitles its holder to purchase one common share of Titan at a price of $0.24 for a period of five years from the date of grant.

14 Sep 2009